The prognostic significance of cell cycle markers in esophageal cancer after neoadjuvant chemotherapy

Diseases of the Esophagus

Volumn 12, Issue 2, 1999, Pages 120-127

  Yasunaga, M ^a,b   Tabira, Y ^a   Kondo, K ^a   Okuma, T ^a,c   Kitamura, N ^a  

^a KUMAMOTO UNIVERSITY   (Japan)

^b Yamaga City Hospital   (Japan)

^c Izumi City Hospital   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; CYCLIN A; CYCLINE; ETOPOSIDE; FLUOROURACIL; METHOTREXATE; MITOMYCIN C; PEPLEOMYCIN; PIRARUBICIN; PROTEIN P27; VINDESINE;

ADJUVANT CHEMOTHERAPY; ADULT; AGED; ARTICLE; CANCER SURVIVAL; CELL CYCLE; CONTROLLED STUDY; ESOPHAGUS CANCER; ESOPHAGUS MUCOSA; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; MITOSIS INDEX; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; PROGNOSIS; SUBMUCOSA;

AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, SQUAMOUS CELL; CYCLIN A; ESOPHAGEAL NEOPLASMS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MICROFILAMENT PROTEINS; MITOTIC INDEX; MUSCLE PROTEINS; PROGNOSIS; PROLIFERATING CELL NUCLEAR ANTIGEN; TUMOR MARKERS, BIOLOGICAL;

EID: 0032800016     PISSN: 11208694     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1442-2050.1999.00031.x     Document Type: Article

References (45)

1. Livstone E M, Skinner D B. Tumors of the esophagus. In: Berk J E, Haubrich W, Kaiser M H, Roth J L A, Schaffer F, eds. Gastroenterology, 4th edn. Philadelphia: W.B. Saunders, 1985: 818-850.
2. Orringer M B, Sloan H. Oesophagectomy without thoracotomy. J Thorac Cardiovasc Surg 1978; 76: 634-654.
3. Akiyama H, Tsurumaru M, Kawamura T et al. Principles of surgical treatment for carcinoma of the esophagus: analysis of lymph node involvement. Ann Surg 1981; 194: 438-445.
4. Postlethwait R W. Complication and deaths after operations for esophageal carcinoma. J Thorac Cardiovasc Surg 1983; 85: 827-831.
5. Hoffmann T H, Kelley J R, Grover F L, Trinkle J K. Carcinoma of the esophagus: an aggressive one-stage palliative approach. J Thorac Cardiovasc Surg 1981; 81: 44-49.
6. MacFarlane S D, Hill L D, Jolly P C et al. Improved results of surgical treatment for esophageal and gastroesophageal junction carcinomas after preoperative combined chemotherapy and radiation. J Thorac Cardiovasc Surg 1988; 95: 415-422.
7. Wolfe W G, Burton G V, Seigler H F et al. Early results with combined modality therapy for carcinoma of the esophagus. Ann Surg 1987; 205: 563-568.
8. Kelsen D P. Preoperative chemotherapy in esophageal carcinoma. World J Surg 1987; 11: 433-438.
9. Fisher B, Gunduz N, Saffer E. Influence of the interval between primary tumor removal and chemotherapy on kinetics and growth of metastases. Cancer Res 1983; 15: 33-38.
10. Okuma T, Torigoe Y, Hongoh H et al. Combined therapy with cisplatin and peplomycin for esophageal cancer surgery. Jpn J Gastroenterol Surg 1984; 17: 1973-1979.
11. Kondo K, Okuma T, Yoshioka M et al. Preoperative in vitro chemosensitivity test of esophageal cancer with endoscopic specimens. Cancer 1993; 71: 661-666.
12. Okuma T, Yoshioka M, Isechi S et al. Preoperative chemotherapy for esophageal cancer based on chemosensitivity testing. J Thorac Cardiovasc Surg 1994; 108: 823-829.
13. Hamburger A W, Salmon S E. Primary bioassay of human myeloma stem cells. J Clin Invest 1977; 60: 846-854.
14. Hunter T, Pines J. Cyclin and cancer II: cyclin D and CDK inhibitors come of age. Cell 1994; 79: 573-582.
15. Sherr C J. Cancer cell cycles. Science 1996; 274: 1672-1677.
16. Harper J W, Elledge S J. Cdk inhibitors in development and cancer. Curr Opin Genet Dev 1996; 6: 56-64.
17. Motokura T, Arnold A. Cyclin and oncogenesis. Biochim Biophys Acta 1993; 1155: 68-78.
18. Morgan D O. Principles of CDK regulation. Nature 1995; 374: 131-134.
19. Elias J M. Cell proliferation indexes: a biomarker in solid tumors. Biotec Histochem 1997; 72: 78-85.
20. Kelman Z. PCNA structure, functions and interactions. Oncogene 1997; 14: 629-640.
21. Jaskulsky D, Deriel J K, Mercer W E et al. Inhibition of cellular proliferation by antisense oligodeoxynucleotides to PCNA/cyclin. Science 1988; 240: 1544-1546.
22. Paradiso A, Rabinovich M, Vallejo C et al. p53 and PCNA expression in advanced colorectal cancer: response to chemotherapy and long-term prognosis. Int J Cancer 1996; 69: 437-441.
23. Kinugasa S, Tachibana M, Hishikawa Y et al. Prognostic significance of proliferating cell nuclear antigen (PCNA) in squamous cell carcinoma of the esophagus. Jpn J Cli Oncol 1996; 26: 405-410.
24. Desdouets C, Sobczak-Thepot J et al. Cyclin A. function and expression during cell proliferation. Prog Cell Cycle Res 1995; 1: 115-123.
25. Yu K, Min K, Amol N S R et al. Promoting apoptosis: a novel activity associated with the cyclin-dependent kinase inhibitor p27. Cancer Res 1997; 57: 5441-5445.
26. Craig C, Wersto R, Kim M et al. A recombinant adenovirus expressing p27kip1 induces cell cycle arrest and loss of cyclin-Cdk activity in human breast cancer cells. Oncogene 1997; 14: 2283-2289.
27. Kwon T K, Nordin A A. Overexpression of cyclin E and cyclin-dependent kinase inhibitor (p27Kip1): effect on cell cycle regulation in HeLa cells. Biochem Biophys Res Commun 1997; 238: 534-538.
28. Peggy L, Kathleen E M, Patrick J H et al. Expression of cell-cycle regulators p27kip1 and cyclin E, alone and in combination, correlate with survival in young breast cancer patients. Nature Med 1997; 3: 222-225.
29. Charles C, Nandita B, Yee C U et al. Decreased levels of the cell-cycle inhibitor p27kip1 protein: Prognostic implications in primary breast cancer. Nature Med 1997; 3: 227-230.
30. Massimo L, Barry C, Sun W T et al. Increased proteasome-dependent degradation of the cyclin-dependent kinase inhibitor p27 in aggressive colorectal carcinomas. Nature Med 1997; 3: 231-234.
31. Fredersdorf S, Burns J, Milne A M et al. High Level expression of p27 (kip1) and cyclin D1 in some human breast cancer cells: inverse correlation between the expression of p27 (kip1) and degree of malignancy in human breast and colorectal cancers. Proc Natl Acad Sci USA 1997; 94: 6380-6385.
32. Kuopio T, Collan Y. Mitotic count in breast cancer. Pathol Res Prac 1996; 192: 1095-1099.
33. Matturri L, Biondo B, Lavezzi A M. Thymidine labeling index in colorectal carcinoma: relation to clinicopathological parameters and to mitotic index. Cancer Detec Prev 1997; 21: 471-475.
34. Ross C D, Martin D A, Michael C P. Chemotherapy. In: Martin D A, James O A, Allen S L, John E N, eds Clinical oncology. New York: Churchill Livingstone, 1997: 201-218.
35. Rao R N. Targets for cancer therapy in the cell cycle pathway. Curr Opin Oncol 1996; 8: 516-524.
36. Waga S, Hannon G J, Beach D S et al. The p21 inhibitor of cyclin-dependent kinases controls DNA replication by interaction with PCNA. Nature 1994; 369: 574-578.
37. Chu G. Cellular responses to cisplatin. J Biol Chem 1994; 269: 787-790.
38. Krishnaswamy G, Dewy W C. Cisplatin induced cell killing and chromosomal aberrations in CHO cells treated during G1 or S phase. Mutat Res 1993; 293: 161-172.
39. Donaldson K L, Goolsby G L, Wahl A F. Cytotoxicity of anticancer agents cisplatin and taxol during cell proliferation and the cell cycle. Int J Cancer 1994; 57: 847-855.
40. Sorenson C M, Barry M A, Eastman A. Analysis of events associated with cell cycle arrest at G2 phase and cell death induced by cisplatin. J Natl Cancer Inst 1990; 82: 749-755.
41. Fero M L, Rivkin M, Tasch M et al. A syndrome of multiorgan hyperplasia with features of gigantism, tumorigenesis, and female sterility in p27 (Kip1)-deficient mice. Cell 1996; 84: 733-744.
42. Nakayama K, Ishida N, Shirane M et al. Mice lacking p27 (Kip1) display increased body size, multiple organ hyperplasia, retinal dysplasia, and pituitary tumors. Cell 1996; 85: 707-720.
43. Kiyokawa H, Kineman R D, Manova-Todorova K O et al. Enhanced growth of mice lacking the cyclin-dependent kinase inhibitor function of p27 (Kip1). Cell 1996; 85: 721-732.
44. Hall M, Bates S, Peters G. Evidence for different modes of action of cyclin-dependent kinase inhibitors: p15 and p16 bind to kinases, p21 and p27 bind to cyclins. Oncogene 1995; 11: 1581-1588.
45. Volm M, Koomagi R, Mattern J et al. Cyclin A is associated with an unfavourable outcome in patients with non-small-cell lung carcinoma. Br J Cancer 1997; 75: 1774-1778.